Open AccessTherapeutic effect of cisplatin given with a lymphatic drug delivery system on false‐negative metastatic lymph nodes
Author(s) -
Tada Asuka,
Horie Sachiko,
Mori Shiro,
Kodama Tetsuya
Publication year - 2017
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13387
Subject(s) - medicine , lymph , lymphatic system , systemic administration , cisplatin , drug delivery , indocyanine green , chemotherapy , drug , pharmacology , lymph node , pathology , in vivo , chemistry , microbiology and biotechnology , organic chemistry , biology
Systemic administration of drugs into the blood circulation is standard treatment for prevention of metastasis. However, systemic delivery cannot maintain sufficiently high concentrations of anticancer drugs in lymph nodes ( LN ). Here, we show that giving cisplatin ( CDDP ) using a lymphatic drug delivery system ( LDDS ) has the potential to treat false‐negative metastatic LN . We found that in MXH 10/Mo‐ lpr / lpr mice, which develop systemic swelling of LN up to 10 mm in diameter, accumulation of indocyanine green ( ICG ), which has a similar molecular weight to CDDP , in a target LN was greater for lymphatic delivery of ICG than for systemic (i.v.) administration. Furthermore, CDDP administration with a LDDS inhibited tumor growth in false‐negative metastatic LN and produced fewer adverse effects than systemically given CDDP . We anticipate that drug delivery using a LDDS will, in time, replace systemic chemotherapy for the treatment of false‐negative metastatic LN .